nach oben

Drugs

Erschienen in:

01.04.2004 | Review Article

The Anabolic Androgenic Steroid Oxandrolone in the Treatment of Wasting and Catabolic Disorders

Review of Efficacy and Safety

verfasst von: Rhonda Orr, Maria Fiatarone Singh

Erschienen in: Drugs | Ausgabe 7/2004

Einloggen, um Zugang zu erhalten

Abstract

There has been increasing interest in the development of effective agents that can be safely used to promote anabolism in the clinical setting for patients with chronic wasting conditions as well as in the prevention and treatment of frailty associated with loss of muscle tissue in aging (sarcopenia).

One such agent is the anabolic androgenic steroid (AAS) oxandrolone, which has been used in such clinical situations as HIV-related muscle wasting, severe burn injury, trauma following major surgery, neuromuscular disorders and alcoholic hepatitis for over 30 years. In the US, oxandrolone is the only AAS that is US FDA-approved for restitution of weight loss after severe trauma, major surgery or infections, malnutrition due to alcoholic cirrhosis, and Duchenne’s or Becker’s muscular dystrophy.

Our review of the use of oxandrolone in the treatment of catabolic disorders, HIV and AIDS-related wasting, neuromuscular and other disorders provides strong evidence of its clinical efficacy. Improvements in body composition, muscle strength and function, status of underlying disease or recovery from acute catabolic injury and nutritional status are significant in the vast majority of well designed trials. However, oxandrolone has not yet been studied in sarcopenia.

Unlike other orally administered C17α-alkylated AASs, the novel chemical configuration of oxandrolone confers a resistance to liver metabolism as well as marked anabolic activity. In addition, oxandrolone appears not to exhibit the serious hepatotoxic effects (jaundice, cholestatic hepatitis, peliosis hepatis, hyperplasias and neoplasms) attributed to the C17α-alkylated AASs. Oxandrolone is reported to be generally well tolerated and the most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level.

However, optimal risk: benefit ratios for oxandrolone and other agents in its class will need to be refined before widespread clinical acceptance of AASs as a therapeutic option in sarcopenia and other chronic wasting conditions.

Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic disease. J Clin Endocrinol Metab 2001; 86(11): 5108–17PubMedCrossRef

Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002; 57: 411–34PubMedCrossRef

Sheffield-Moore M, Urban R, Wolf SE, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 1999; 84(8): 2705–11PubMedCrossRef

Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3469–75PubMedCrossRef

Hasten DL, Pak-Loduca J, Obert KA, et al. Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78–84 and 23–32 yr olds. Am J Physiol Endocrinol Metab 2000; 278(4): E620–6PubMed

Ferrando AA, Sheffield-Moore M, Wolf SE, et al. Testosterone administration in sever burns ameliorates muscle catabolism. Crit Care Med 2001; 29(10): 1936–42PubMedCrossRef

Urban R, Bodenburgh Y, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: E820–6PubMed

Kutscher EC, Lund BC, Perry PJ. Anabolic steroids a review for the clinician. Sports Med 2002; 32(5): 285–96PubMedCrossRef

Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335(1): 1–7PubMedCrossRef

10.

Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003; 51(1): 101–15PubMedCrossRef

11.

Fox M, Minot AS, Liddle GW. Oxandrolone: a potent anabolic steroid of novel chemical configuration. J Clin Endocrinol Metab 1962; 22: 921–4PubMedCrossRef

12.

Gerondache CN, Dowling WJ, Pincus G. Metabolic changes induced in elderly patients with an anabolic steroid (oxandrolone). J Gerontol 1967; 22(3): 290–300CrossRef

13.

Karim A, Ranney R, Zagarella J, et al. Oxandrolone disposition and metabolism in man. Clin Pharmacol Ther 1973; 14(5): 862–9PubMed

14.

Harrison L, Martin D, Gotlin R, et al. Effect of extended use of single anabolic steroids on urinary steroid excretion and metabolism. J Chromatogr 1989; 489(1): 121–6PubMedCrossRef

15.

Bi H, Masse R. Studies on anabolic steroids. 12: epimerization and degradation of anabolic 17 beta-sulfate-17 alpha-methyl steroids in human: qualitative and quantitative CG/MS analysis. J Steroid Biochem Mol Biol 1992; 42(5): 533–46

16.

Albanese A, Lorenze E, Orto L. Nutritional and metabolic effects of some newer steroids. N Y State J Med 1962; 62: 1607–16PubMed

17.

Link K, Blizzard R, Evans W, et al. The effect of androgens on the pulsatile release and the twenty-four hour mean concentration of growth hormone in peripubertal males. J Clin Endocrinol Metab 1986; 62(1): 159–64PubMedCrossRef

18.

Lennon D, Saunders F. Anabolic activity of 2-oxa-17-alpha methyldihydrotestosterone (oxandrolone) in castrated rats. Steroids 1964; 4: 689–97CrossRef

19.

Jackson S, Rallison M, Buntin W, et al. Use of oxandrolone for growth stimulation in children. Am J Dis Child 1973; 126: 481–4PubMed

20.

Mendenhall CL, Moritz TE, Roselle GA, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group # 275. JPEN J Parenter Enteral Nutr 1995; 19(4): 258–65PubMedCrossRef

21.

Mendenhall CL, Moritz TE, Roselle GA, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17(4): 564–76PubMedCrossRef

22.

Bonkovsky HL, Fiellin DA, Slaker DP, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I: short-term effects on liver function. Am J Gastroenterol 1991; 86(9): 1200–8

23.

Bonkovsky HL, Singh RH, Jafri IH, et al. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II: short-term effects on nitrogen metabolism, metabolic balance, and nutrition. Am J Gastroenterol 1991; 86(9): 1209–18

24.

Mendenhall CL, Anderson S, Garcia-Pont P, et al. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311(23): 1464–70PubMedCrossRef

25.

Demling R, DeSanti L. The anabolic steroid, oxandrolone, reverses the wound healing impairment in corticosteroid-dependent burn and wound patients. Wounds 2001; 13(5): 203–8

26.

Demling R, DeSanti L. The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone, is not age dependent. Burns 2001; 27(1): 46–51PubMedCrossRef

27.

Demling R, Orgill D. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 2000; 15(1): 12–7PubMedCrossRef

28.

Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001; 233(4): 556–64PubMedCrossRef

29.

Morton R, Gleason O, Yates W. Psychiatric effects of anabolic steroids after burn injuries. Psychosomatics 2000; 41(1): 66–8PubMedCrossRef

30.

Demling R. Comparison of the anabolic effects and complications of human growth hormone and the testosterone analog, oxandrolone, after severe burn injury. Burns 1999; 25(3): 215–21PubMedCrossRef

31.

Demling RH, DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma 1997; 43(1): 47–51PubMedCrossRef

32.

Aleem RF, Walaszek PS, Gamelli RL. Effect of oxandrolone on outcome in patients with thermal injury [abstract]. J Burn Care Rehabil 1999; 20(1): S199

33.

Demling RH, DeSanti L. The beneficial effects of the anabolic steroid oxandrolone in the geriatric burn population. Wounds 2003; 15(2): 54–8

34.

Gervascio JM, Dickerson RN, Swearingen J, et al. Oxandrolone in trauma patients. Pharmacotherapy 2000; 20(11): 1328–34CrossRef

35.

Yeh S, DeGuzman B, Kramer T. Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 2002; 122(2): 421–8PubMedCrossRef

36.

Bowen RE, Dutko L, Christman S. The effects of oxandrolone on performance in patients with COPD [abstract]. Chest 1998; 114 Suppl. 4: 318SCrossRef

37.

Kravetz JD, Lee C, Dietrich DT. Oxandrolone use in Crohn’s disease. Am J Gastroenterol 1997; 92(12): 2230–1

38.

Cioroiu M, Hanan SH. Adjuvant anabolic agents: a case report on the successful use of oxandrolone in an HIV-positive patient with chronic stasis ulceration. J Wound Ostomy Continence Nurs 2001; 28(4): 215–8PubMed

39.

Earthman CP, Reid PM, Harper IT, et al. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. JPEN J Parenter Enteral Nutr 2002; 26(6): 357–65PubMedCrossRef

40.

Fox-Wheeler S, Heller L, Salata C, et al. Evaluation of the effects of oxandrolone in malnourished HIV-positive pediatric patients. Pediatrics 1999; 104(6): E731–7CrossRef

41.

Romeyn N, Gunn N. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA 2000; 284(2): 176–7PubMedCrossRef

42.

Strawford A, Barbieri T, Loan MV, et al. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 1999; 281(14): 1282–90PubMedCrossRef

43.

Fisher A, Abbaticola M, The Oxandrolone Study Group. The effects of oxandrolone on the body composition in patients with HIV-associated weight loss [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–15; Chicago

44.

Pharo A, Salvato P, Vergel N, et al. Oxandrolone: anabolic steroid use in HIV positive women [abstract]. Nutrition 1997; 13(3): 268CrossRef

45.

Poles M, Meller J, Lin A, et al. Oxandrolone as a treatment for HIV-associated weight loss: a one year follow up [abstract]. Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto

46.

Salvato P, Thompson C, Vergel N, et al. Anabolic steroid use in HIV/AIDS patients [abstract]. Nutrition 1997; 13(3): 268CrossRef

47.

Fisher A, Abbaticola M. Effects of oxandrolone and l-glutamine on body weight, body cell mass, and body fat in patients with HIV infection: preliminary analysis [abstract]. Nutrition 1997; 13(3): 279CrossRef

48.

Berger JR, Pall L, Hall CD, et al. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10: 1657–62PubMedCrossRef

49.

Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001; 56(8): 1075–9PubMedCrossRef

50.

Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58: 1081–7PubMedCrossRef

51.

Rosenfeld J, King RM, Smith JE. Oxandrolone in ALS: preliminary analysis. Amyotroph Lateral Schier Other Motor Neuron Disord 2000; 1 Suppl. 4: 21–5

52.

Fenichel G, Pestronk A, Florence J, et al. A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study. Neurology 1997; 45(5): 1225–6CrossRef

53.

Spungen AM, Koehler KM, Modeste-Duncan R, et al. 9 clinical cases of nonhealing pressure ulcers in patients with spinal cord injury treated with an anabolic agent: a therapeutic trial. Adv Skin Wound Care 2001 May/Jun; 14(3): 139–44PubMedCrossRef

54.

Spungen AM, Grimm DR, Strakhan M, et al. Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study. Mt Sinai J Med 1999; 66(3): 201–5PubMed

55.

Demling R, DeSanti L. Closure of the ‘non-healing’ wound corresponds with correction of weight loss using the anabolic agent oxandrolone. Ostomy Wound Manage 1998; 44(10): 58–62, 64, 66 passimPubMed

56.

Barakat AJ, Castaldo AJ. Successful use of oxandrolone in the prophylaxis of hereditary angioedema: a case report. Pediatr Asthma Allergy Immunol 1999; 13(4): 189–93CrossRef

57.

Lovejoy J, Bray G, Greeson C, et al. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obes Relat Metab Disord 1995; 19(9): 614–24PubMed

58.

Malmendier CL, van den Bergen CJ, Emplit G, et al. A long-term study of the efficacy of oxandrolone in hyperlipoproteinemias. J Clin Pharmacol 1978; 18(1): 42–53PubMed

59.

Enholm C, Huttunen JK, Kinnunen PJ, et al. Effect of oxandrolone treatment on the activity of lipoprotein lipase, hepatic lipase and phospholipase al of human postheparin plasma. N Engl J Med 1975; 292: 1314–7CrossRef

60.

Doyle A, Pinkus N, Green J. The use of oxandrolone in hyperlipidaemia. Med J Aust 1974; 1: 127–9PubMed

61.

Segal S, Cooper J, Bolognia J. Treatment of lipodermatosclerosis with oxandrolone in a patient with stanozolol-induced hepatotoxicity. J Am Acad Dermatol 2000; 43(3): 558–9PubMedCrossRef

62.

Sansoy OM, Roy AN, Shields LM. Anabolic action and side effects of oxandrolone in 34 mental patients. Geriatrics 1971; 26: 139–43PubMed

63.

Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984; 12(6): 469–83PubMedCrossRef

64.

Graham S, Kennedy M. Recent developments in the toxicity of anabolic steroids. Drug Saf 1990; 5(6): 458–76PubMedCrossRef

65.

Stone MH. Literature review: anabolic-androgenic steroid use by athletes. Nat Strength Condit Assoc J 1993; 15(2): 10–28CrossRef

66.

Bahrke MS, Yesalis CE, Wright JE. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. Sports Med 1996; 22(6): 367–90PubMedCrossRef

67.

Yesalis CE. Anabolic steroids in sport and exercise. Champaign (IL): Human Kinetics, 2000

68.

Parssinen M, Seppala T. Steroid use and long-term health risks in former athletes. Sports Med 2002; 32(2): 83–94PubMedCrossRef

69.

Winwood P, Robertson D, Wright R. Bleeding oesophageal varices associated with anabolic steroid use in an athlete. Postgrad Med J 1990; 66: 864–5PubMedCrossRef

70.

Maddrey W. Is therapy with testosterone or anabolic-androgenic steroids useful in the treatment of alcoholic liver disease? Hepatology 1986; 6: 1033–5PubMedCrossRef

71.

Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/ androgenic steroids. Semin Liver Dis 1987; 7(3): 230–6PubMedCrossRef

72.

Kelley V, Ruvalcaba R. Use of anabolic agents in the treatment of short children. Clin Endocrinol Metab 1982; 11: 25–39PubMedCrossRef

73.

Friedl KE. Effects of anabolic steroids on physical health. In: Yesalis CE, editor. Anabolic steroids in sport and exercise. 2nd ed. Champaign (IL): Human Kinetics, 2000: 175–223

74.

Zimmerman HJ, Ishak KG. Steroids and other hormones. In: Cameron RG, Feuer G, de la Iglesia FA, editors. Drug-induced hepatotoxicity. Berlin: Springer-Verlag, 1996: 543–79CrossRef

75.

Wilson J, Griffin J. The use and abuse of androgens. Metabolism 1980; 29: 1278–90PubMedCrossRef

76.

Raiti S, Trias E, Levitsky L, et al. Oxandrolone and human growth hormone: comparison of growth-stimulating effects in short children. Am J Dis Child 1973; 126: 597–600PubMed

77.

Danowski TS, Lee FA, Cohn RE, et al. Oxandrolone therapy of growth retardation. Am J Dis Child 1965; 109: 526–32PubMed

78.

Naeraa R, Nielsen J, Pedersen I, et al. Effect of oxandrolone on growth and final height in Turner’s syndrome. Acta Pediatr Scand 1990; 79: 784–9CrossRef

79.

Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23(9): 1355–89PubMedCrossRef

80.

Dickerman RD, Pertusi RM, Zachariah NY, et al. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999; 9: 34–9PubMedCrossRef

81.

Slater S, Davidson J, Patrick R. Jaundice induced by stanozolol hypersensitivity. Postgrad Med J 1976; 52(606): 229–32PubMedCrossRef

82.

Holder L, Gnarra D, Lampkin B, et al. Hepatoma associated with anabolic steroid therapy. Am J Roentgenol Radium Ther Nucl Med 1975; 124: 638–42PubMed

83.

Boue F, Coffin B, Delfraissy J. Danazol and cholestatic hepatitis. Ann Intern Med 1986; 105(1): 139–40PubMed

84.

Bray G, Tredger J, Williams R. Resolution of danazol-induced cholestasis with s-adenosylmethionine. Postgrad Med J 1993; 69(809): 237–9PubMedCrossRef

85.

Ohsawa T, Iwashita S. Hepatitis associated with danazol. Drug Intell Clin Pharm 1986; 20: 889PubMed

86.

Borhan-Manesh F, Farnum JB. Methyltestosterone-induced cholestasis: the importance of disproportionately low serum alkaline phosphatase level. Arch Intern Med 1989; 124: 2127–9CrossRef

87.

Evely R, Triger D, Milnes J, et al. Severe cholestasis associated with stanozolol. BMJ 1987; 294: 612–3PubMedCrossRef

88.

Goldenberg I. Hormonal therapy of women for metastatic carcinoma. Cancer Chemother 1965; 44: 49–51

89.

Paradinas F, Bull T, Westaby D, et al. Hyperplasia and prolapse of hepatocytes into hepatic veins during long term methyltestosterone therapy: possible relationships of these changes to the development of peliosis hepatis and liver tumors. Histopathology 1977; 1: 225–6PubMedCrossRef

90.

Bagheri S, Boyer J. Peliosis hepatis associated with androgenic-anabolic steroid therapy: a severe form of hepatic injury. Ann Intern Med 1974; 81: 610–8PubMed

91.

Kintzen W, Silny J. Peliosis hepatis after administration of fluoxymesterone. CMAJ 1960; 83: 860–2

92.

Groos G, Arnold O, Brittinger G. Peliosis hepatis after long-term administration of oxymetholone [letter]. Lancet 1974; I(7826): 874CrossRef

93.

McDonald EC, Speicher CE. Peliosis hepatis associated with administration of oxymetholone. JAMA 1978; 240(3): 243–4PubMedCrossRef

94.

Bernstein M, Hunter R, Yachnin S. Hepatoma and peliosis hepatis developing in a patient with Fanconi’s anemia. N Engl J Med 1971; 284(20): 1135–6PubMedCrossRef

95.

Arnold G, Kaplan M. Peliosis hepatis due to oxymetholone: a clinically benign disorder. Am J Gastroenterol 1979; 71: 213–6PubMed

96.

Makdisi W, Cherian R, Vanveldhuizen P, et al. Fatal peliosis of the liver and spleen in a patient with agnogenic myeloid metaplasia treated with danazol. Am J Gastroenterol 1995; 90(2): 317–8PubMed

97.

Cabasso A. Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 1994; 26: 2–4PubMed

98.

Westaby D, Ogle S, Paradinas F, et al. Liver damage from long-term methyltestosterone. Lancet 1977; II(8032): 261–3CrossRef

99.

Alberti-Flor J, Iskandarani M, Jeffers L, et al. Focal nodular hyperplasia associated with the use of a synthetic anabolic androgen. Am J Gastroenterol 1984; 79(2): 150–1PubMed

100.

Fermand J, Levy Y, Bouscary D, et al. Danazol-induced hepatocellular adenoma. Am J Med 1990; 88(5): 529–30PubMedCrossRef

101.

Bork K, Pitton M, Harten P, et al. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999; 353: 1066–7PubMedCrossRef

102.

Anthony P. Hepatoma associated with androgenic steroids. Lancet 1975; I(7908): 685–6CrossRef

103.

Bruguera M. Hepatoma associated with androgenic steroids [letter]. Lancet 1975; I: 1295

104.

Hernandez-Nieto L, Bruguera M, Bombi J, et al. Benign liver-cell adenoma associated with long-term administration of androgenic-anabolic steroid (methandienone). Cancer 1977; 40(4): 1761–4PubMedCrossRef

105.

Overly W, Dankoff J, Wang B, et al. Androgens and hepatocellular carcinoma in an athlete. Ann Intern Med 1984; 100(1): 158–9PubMed

106.

Creagh T, Rubin A, Evans D. Hepatic tumours induced by anabolic steroids in an athlete. J Clin Pathol 1988; 41(4): 441–3PubMedCrossRef

107.

Goldman B. Liver carcinoma in an athlete taking anabolic steroids [letter]. J Am Osteopath Assoc 1985; 85: 56PubMed

108.

Edis AL, Levitt M. Anabolic steroids and colon cancer. Med J Aust 1985; 142: 426–7PubMed

109.

Johnson FL, Feagler JR, Lerner KG, et al. Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 1972; II(7790): 1273–6CrossRef

110.

Henderson JT, Richmond J, Sumerling MD. Androgenic-anabolic steroid therapy and hepatocellular carcinoma [letter]. Lancet 1973; I(7809): 934CrossRef

111.

Farrell G, Joshua D, Uren R, et al. Androgen-induced hepatoma. Lancet 1975; I(7904): 430–1CrossRef

112.

Lesna M, Spencer I, Walker W. Liver nodules and androgens [letter]. Lancet 1976; I(7969): 1124CrossRef

113.

Mokrohisky ST, Ambruso DR, Hathaway WE. Fulminant hepatic neoplasia after androgen therapy. N Engl J Med 1977; 296(24): 1411–2PubMedCrossRef

114.

Shapiro P, Ikeda R, Ruebner B, et al. Multiple hepatic tumours and peliosis hepatis in Fanconi’s anemia treated with androgens. Am J Dis Child 1977; 131: 1104–6PubMed

115.

Carrasco D, Prieto M, Pallardo L, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate: review of the literature. J Hepatol 1985; 1: 573–8PubMedCrossRef

116.

Griffin JE, Ojeda SR. Textbook of endocrine physiology. 4th ed. New York: Oxford University Press, 2000

117.

Rosenberg IH. Summary comments. Am J Clin Nutr 1989; 50: 1231–3

118.

Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci 2000; 55A(12): M716–24CrossRef

119.

Roubenoff R, Heymsfield SB, Kehayias JJ, et al. Standardization of nomenclature of body composition in weight loss. Am J Clin Nutr 1997; 66: 192–6PubMed

120.

Zoico E, Roubenoff R. The role of cytokines in regulating protein metabolism and muscle function. Nutr Rev 2002; 60(2): 39–51PubMedCrossRef

121.

Richelson L, Wahner H, Melton L, et al. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984; 311(20): 1273–5PubMedCrossRef

122.

Davidson B, Ross R, Paganini-Hill A, et al. Total and free estrogens and androgens in post-menopausal women with hip fractures. J Clin Endocrinol Metab 1982; 54: 115-20PubMedCrossRef

Titel: The Anabolic Androgenic Steroid Oxandrolone in the Treatment of Wasting and Catabolic Disorders
Review of Efficacy and Safety
verfasst von: Rhonda Orr
Maria Fiatarone Singh
Publikationsdatum: 01.04.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 7/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464070-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2004

Ethinylestradiol/Chlormadinone Acetate

Ethinylestradiol/Chlormadinone Acetate

Disseminated Mycobacterium avium-intracellulare Complex (MAC) Infection in the Era of Effective Antiretroviral Therapy

Ethinylestradiol/Chlormadinone Acetate

Ethinylestradiol/Chlormadinone Acetate

Inhaled Iloprost